Given the demonstrated role of GREM1 in imposing a stem cell phenotype on cells outside the crypt base, it seems plausible that the poor treatment response may be secondary to an effect of GREM1 on cancer stem cell plasticity. The gene discussed is GREM1; the disease is cancer.